A study of CD33 (SIGLEC‐3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing

@article{HernndezCaselles2006ASO,
  title={A study of CD33 (SIGLEC‐3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing},
  author={Trinidad Hern{\'a}ndez-Caselles and Mar{\'i}a Mart{\'i}nez-Esparza and Ana B. P{\'e}rez-Oliva and Ana M. Quintanilla‐Cecconi and Ana Mar{\'i}a Garc{\'i}a-Alonso and D. Mar{\'i}a Roc{\'i}o Alvarez‐L{\'o}pez and Pilar Garc{\'i}a-Pe{\~n}arrubia},
  journal={Journal of Leukocyte Biology},
  year={2006},
  volume={79}
}
The expression of CD33, a restricted leukocyte antigen considered specific for myeloid lineage, has been studied extensively on lymphoid cells. We demonstrated that wide subsets of mitogen‐ or alloantigen‐activated human T and natural killer (NK) cells express CD33 at protein and nucleic acid levels. CD33+ and CD33– T and NK cell populations showed identical surface expression of activation markers such as CD25, CD28, CD38, CD45RO, or CD95. Myeloid and lymphoid CD33 cDNA were identical. However… 
Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells.
TLDR
The unique ability of HIM3-4 mAb to detect the masking state of CD33 on different cell lineages makes it a good tool to improve the knowledge of the biological role of this sialic acid-binding Ig-like lectin.
Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation1
TLDR
Three additional CD160-related mRNAs generated through alternative splicings of the CD160 gene are reported, among which one encoded a putative CD160 transmembrane isoform (CD160-TM), which provides new possibilities regarding the role of CD160 isoforms in the regulation of NK cell functions.
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
TLDR
A greater-than-previously thought complexity of CD33 expression in human AML is document and CD33 variants that lack exon 2 are identified and are not recognized by current CD33-directed therapeutics as potential target for future unconjugated or conjugated antibodies.
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
TLDR
The results suggest that CD123 CAR T cells are a promising immunotherapy for the treatment of high-risk AML.
CD33 (Siglec-3) Inhibitory Function: Role in the NKG2D/DAP10 Activating Pathway
TLDR
The results support the role of CD33 as an inhibitory receptor preferentially regulating the NKG2D/DAP10 cytotoxic signaling pathway, which could be involved in self-tolerance and tumor and infected cell recognition.
IMMUNOBIOLOGY T cells expressing CD 123-speci fi c chimeric antigen receptors exhibit speci fi c cytolytic effector functions and antitumor effects against human acute myeloid leukemia
TLDR
The generation of 2 novel CD123-targeting CARs using scFvs from previously described recombinant immunotoxins, 26292 and 32716, which bind distinct epitopes and have similar binding affinities for CD123 are described.
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
TLDR
It is shown that both these modified T cells are very efficient in reducing leukemia burden in vivo, but only the anti-CD123 CAR has limited killing on normal HSPCs, thus making it a very attractive immunotherapeutic tool for AML treatment.
Antigen Presenting Properties of a Myeloid Dendritic-Like Cell in Murine Spleen
TLDR
The L-DC gene profile is quite distinct from that of cDC, confirming a myeloid cell type with distinct antigen presenting properties.
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
TLDR
A promising strategy for redirecting primary human NK cells in response to TBs against leukemia is demonstrated, which may lead to a future progress in NK cell-based immunotherapies.
Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia
TLDR
B bispecific T-cell–engaging antibody AMG 330 with dual specificity for CD3 and the sialic acid–binding lectin CD33 mediated autologous depletion of CD33-positive cells from cynomolgous monkey bone marrow aspirates warrants further development as a potential therapy for AML.
...
...

References

SHOWING 1-10 OF 57 REFERENCES
Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
TLDR
The results suggest that while CD86 is expressed on a number of different cell types, its costimulatory function and affinity for its ligands may be regulated by cell type-specific post-translational modifications.
Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors
TLDR
A regulatory role of CD33 is suggested in the myeloid cell maturation and may offer a tool to interfere with the monocyte / macrophage cell function as well as with the development of dendritic cells.
In vitro infection of CD4+ T lymphocytes with HTLV-I generates immortalized cell lines coexpressing lymphoid and myeloid cell markers
TLDR
The data suggest that the presence of both myeloid and lymphoid phenotype in HTLV-I infected T cells is the results of an induction rather than a selection mechanism.
Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells.
TLDR
A cDNA clone encoding the human myeloid Ag CD33 was isolated from a U937 cDNA library after three rounds of transient expression in COS cells and enrichment by panning, and transcripts were found constitutively expressed in several myeloids progenitor cell lines.
The Myeloid-specific Sialic Acid-binding Receptor, CD33, Associates with the Protein-tyrosine Phosphatases, SHP-1 and SHP-2*
TLDR
CD33 signaling through selective recruitment of SHP-1/SHP-2 may modulate its ligand(s) binding activity, and mutation of tyrosine 340 increased red blood cell binding by CD33 expressed in COS cells.
Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny.
TLDR
TdT+ lymphoid precursors in pediatric BM are reevaluate to define the phenotypic denominator of B-lineage affiliation upstream of CD19 and confirm that the earliest differentiation stages of B cells can be dissected upon expression of the lineage antigens CD79a and CD19, and imply thatCD79a is earlier expressed than CD19.
Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.
TLDR
It is demonstrated that CD33 is tyrosine phosphorylated in the presence of the phosphatase inhibitor, pervanadate, and recruits SHP-1 andSHP-2, implying that CD 33 is an inhibitory receptor and also that SHP -1 phosph atase has a significant role in mediating CD33 function.
ICAM‐3, the third LFA‐1 counterreceptor, is a co‐stimulatory molecule for both resting and activated T lymphocytes
TLDR
The data suggest that ICAM‐3 on the surface of both T cells and antigen‐presenting cells plays an essential role in the initiation of the immune response.
...
...